Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetic predictors of toxicity and outcomes in NSCLC patients receiving chemoradiation or platinum chemotherapy
NL-OMON47255Active, not recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Feb 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cisplatin and carboplatin in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by St. Antonius Ziekenhuis. Primary endpoints: Esophagitis severity, Nephrotoxicity severity and 2 more. Started Feb 2016; status: active, not recruiting.
02
Drugs
cisplatincarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON47255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47255.